Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open label, multicenter, Phase 2 study comparing two dose schedules of
Telintra in patients with Low or Intermediate-1 risk MDS. Patients at least 18 years of age
presenting with histologically confirmed Low to Intermediate-1 risk MDS with documented
significant cytopenia for at least two months by the IWG criteria are eligible.